Unityaxone 2g (Ceftriaxone Sodium Hydrate)

Adult administration

Adults and children over 12 years: 1-2g (activity) of ceftriaxone is administered intravenously or intramuscularly once daily. In cases of severe disease caused by moderately susceptible pathogens, the dosage may be increased to 4g (activity) once daily. Elderly: There is no need to change the dosage for adults.

Child administration

For newborns (within 14 days of birth), 20-50mg (activity) per kg of body weight is administered once daily and should not exceed 50mg (activity) per kg. It is not necessary to distinguish between premature and term infants.

This medication must not be mixed or administered simultaneously with calcium-containing solutions or drugs. In particular, it should not be administered to newborns, as there is a risk of precipitation from calcium interaction. Patients with an allergy to this drug or who have had hypersensitivity reactions to cephalosporins or penicillin antibiotics should not use this medication. It should also not be given to premature infants or to newborns with jaundice or issues with bilirubin binding. Patients with a history of drug allergies or those prone to asthma, rashes, or hives should use this medication cautiously. Elderly patients or those with severely impaired kidney function or a generally poor health status should also exercise caution. Using this medication can cause various side effects, including changes in blood cell count, diarrhea, rash, and liver function abnormalities. If any unusual symptoms occur, immediate consultation with healthcare professionals is necessary. Rarely, severe allergic reactions or neurological abnormalities have also been reported. Patients should be monitored closely for their condition upon administration, and regular kidney and liver function tests should be performed if necessary. Additionally, this medication may affect driving or machinery operation capabilities, so caution is required. Women who are pregnant or breastfeeding should use this medication cautiously, and it should not be given to newborns or premature infants due to the risk of bilirubin encephalopathy. When used in combination with other drugs, it can affect kidney function, so consulting a doctor is essential, particularly when used with diuretics or aminoglycoside antibiotics. This drug can detach bilirubin from serum albumin, posing a risk for newborns, so it should not be used in infants with high bilirubin levels. In case of overdose, as there is no specific antidote, symptomatic treatment should be received, and the prepared solution should be used as soon as possible.

Serious side effects

Hives, severe swelling (edema), difficulty breathing, anaphylaxis and anaphylactoid reactions, severe allergic reactions, severe skin adverse reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), liver abnormalities (jaundice), encephalopathy, severe renal impairment, acute renal failure of renal origin, severe neurological symptoms (encephalopathy, confusion, seizures), severe edema or urination abnormalities (severe edema, oliguria), serum sickness, hemolytic anemia

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• nausea

This medication should be stored in a sealed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 to 30 degrees Celsius at room temperature.

Appearance

It is a colorless, transparent vial containing a white to light yellow powder.

Package unit

2g x 10 vials